Acquisition by Rubin Jami of 102225 shares of Relay Therapeutics at 6.79 subject to Rule 16b-3
| RLAY Stock | USD 4.70 0.10 2.08% |
Slightly above 67% of Relay Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Relay Therapeutics suggests that many traders are alarmed. Relay Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Relay Therapeutics' earnings reports, geopolitical events, and overall market trends.
Relay |
Filed transaction by Relay Therapeutics Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Relay Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Relay Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Relay Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Relay Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Relay Therapeutics Fundamental Analysis
We analyze Relay Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Relay Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Relay Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Relay Therapeutics is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Relay Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Relay Therapeutics stock to make a market-neutral strategy. Peer analysis of Relay Therapeutics could also be used in its relative valuation, which is a method of valuing Relay Therapeutics by comparing valuation metrics with similar companies.
Peers
Relay Therapeutics Related Equities
| GLUE | Monte Rosa | 13.72 | ||||
| CCCC | C4 Therapeutics | 8.59 | ||||
| IPSC | Century Therapeutics | 5.52 | ||||
| NRIX | Nurix Therapeutics | 4.15 | ||||
| BDTX | Black Diamond | 3.11 | ||||
| ARVN | Arvinas | 2.85 | ||||
| CGEM | Cullinan Oncology | 2.75 | ||||
| FHTX | Foghorn Therapeutics | 2.57 | ||||
| EWTX | Edgewise Therapeutics | 2.48 | ||||
| PLRX | Pliant Therapeutics | 2.00 | ||||
| STOK | Stoke Therapeutics | 1.68 | ||||
| DAWN | Day One | 1.53 | ||||
| BPMC | Blueprint Medicines | 1.35 | ||||
| APLS | Apellis Pharmaceuticals | 0.62 | ||||
| TERN | Terns Pharmaceuticals | 1.58 | ||||
| MLYS | Mineralys Therapeutics, | 2.59 | ||||
| AMLX | Amylyx Pharmaceuticals | 3.48 |
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.